Influence of Prior Exposure to Zidovudine on Stavudine Phosphorylation In Vivo and Ex Vivo

ABSTRACT Intracellular phosphorylation of stavudine (d4T) and zidovudine (ZDV) was investigated in peripheral blood mononuclear cells (PBMCs) isolated from ZDV-naive and ZDV-experienced human immunodeficiency virus (HIV)-positive patients. An in vivo study measured the amount of d4T triphosphate (d4TTP), while an ex vivo study assessed the capacity of cells to phosphorylate added d4T. Endogenous dTTP was also measured. d4TTP and dTTP were determined in vivo using a reverse transcriptase chain termination assay. In ex vivo studies, d4T (1 μM) was incubated in resting and phytohemagglutinin-stimulated (10 μg ml−1; 72 h) PBMCs for 24 h. After washing and methanol extraction, radiolabeled anabolites were detected by high-performance liquid chromatography. d4TTP reached its highest level 2 to 4 h after dosing (0.21 ± 0.14 pmol/106cells; n = 27 [mean ± standard deviation]). Comparison of ZDV-naive and ZDV-experienced individuals showed no significant difference in levels of d4TTP (ZDV naive, 0.23 ± 0.17 pmol/106 cells [n = 7] versus ZDV experienced, 0.20 ± 0.14 pmol/106 cells [n = 20]; P = 0.473) or the d4TTP/dTTP ratio (0.14 ± 0.12 [n = 7] and 0.10 ± 0.08 [n = 20], respectively;p = 0.391). Ex vivo data demonstrated no significant difference in the formation of d4TTP or total d4T phosphates in naive and experienced patients (0.086 ± 0.055 pmol/106cells in ZDV-naive patients [n = 17] versus 0.081 ± 0.038 pmol/106 cells in ZDV-experienced patients [n = 22]; P = 0.767). The ability of HIV-infected patients to phosphorylate d4T in vivo and ex vivo was unchanged with increasing exposure to ZDV.

[1]  C. Hart,et al.  Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. , 1998, AIDS research and human retroviruses.

[2]  V. Calvez,et al.  Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection , 1998, Annals of Internal Medicine.

[3]  B. Jacobsson,et al.  Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals. , 1998, Biochemical pharmacology.

[4]  A. Breckenridge,et al.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites , 1996, AIDS.

[5]  J. Rodman,et al.  A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. , 1996, The Journal of infectious diseases.

[6]  B. Jacobsson,et al.  Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism. , 1995, AIDS research and human retroviruses.

[7]  N. Beeching,et al.  Zidovudine phosphorylation in HIV‐infected patients and seronegative volunteers , 1994, AIDS.

[8]  H. Mitsuya,et al.  Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. , 1994, The Journal of biological chemistry.

[9]  J. Rodman,et al.  Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells , 1994, Antimicrobial Agents and Chemotherapy.

[10]  V. Avramis,et al.  Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection. , 1993, Journal of acquired immune deficiency syndromes.

[11]  K. Adubofour.  HIV/AIDS seroincidence/seroprevalence studies from Africa. , 1993, Journal of acquired immune deficiency syndromes.

[12]  S. Broder,et al.  Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.

[13]  M. Clerici,et al.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. , 1989, The Journal of clinical investigation.

[14]  J. A. Fyfe,et al.  Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. , 1989, Analytical biochemistry.

[15]  H. Ho,et al.  Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus , 1989, Antimicrobial Agents and Chemotherapy.

[16]  K. Weinhold,et al.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase , 1987, Antimicrobial Agents and Chemotherapy.

[17]  Broder,et al.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Munch‐Petersen,et al.  The deoxyribonucleoside 5'-triphosphate (dATP and dTTP) pool in phytohemagglutinin-stimulated and non-stimulated human lymphocytes. , 1973, Experimental cell research.

[19]  J. Činátl,et al.  Viral and cellular factors for resistance against antiretroviral agents. , 1997, Intervirology.

[20]  H. Rabenau,et al.  Failure of antiretroviral therapy: role of viral and cellular factors. , 1994, Intervirology.

[21]  E. De Clercq.  HIV inhibitors targeted at the reverse transcriptase. , 1992, AIDS research and human retroviruses.